HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while C-3 modified betulinic acid derivatives function by blocking virus maturation. [127] Among these bevirimat (Figure 23 ...

Although it is known that molecules with anti-HIV activity circulate in human blood, their identification has been hampered by difficulties in the purification and characterization of such compounds.

and marketed by Roche Pharmaceuticals) offers a new and fourth class of antiretroviral agents called fusion (or entry) inhibitors. Enfuvirtide was approved for use in treatment-experienced ...

There is strong evidence that PRM-A is a viral entry inhibitor; in other words, it stops viruses from entering a host's cells. It does this by binding to N-glycans, which are found on the surface ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of HDV ...